Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Patent
1995-06-07
1999-03-09
Stanton, Brian R.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
424 931, 424 932, 424 9321, 4351723, 4351724, 4352351, 4353201, 435325, 514 2, 530300, 536 231, 536 234, 536 235, 536 2392, 935 23, 935 32, 935 34, A01N 4304, C12N 701, C12N 1509, C12N 1512
Patent
active
058801030
ABSTRACT:
A purified preparation of a peptide consisting essentially of an amino acid sequence identical to that of a segment of a naturally-occurring human protein, said segment being of 10 to 30 residues in length, inclusive, wherein said peptide binds to a human major histocompatibility complex (MHC) class II allotype.
REFERENCES:
patent: 4478823 (1984-10-01), Sanderson
patent: 4681760 (1987-07-01), Fathman
patent: 5130297 (1992-07-01), Sharma et al.
patent: 5580859 (1996-12-01), Felgner et al.
patent: 5589466 (1996-12-01), Felgner et al.
patent: 5591823 (1997-01-01), Hung et al.
patent: 5593972 (1997-01-01), Weiner et al.
patent: 5662896 (1997-09-01), Barber et al.
patent: 5670153 (1997-09-01), Weiner et al.
patent: 5695770 (1997-12-01), Raychaudhuri et al.
patent: 5703055 (1997-12-01), Felgner et al.
patent: 5709860 (1998-01-01), Raychaudhuri et al.
Kriegler, Eurakyotic Control Elements, Gene Transfer and Expression A Laboratory Manual, W.H. Freeman and Company, New York (1991) pp. 3-22.
Felgner and Rhodes, Gene Therapeutics, Nature 349:351-352, 1991.
Kriegler, Vectors, Gene Transfer and Expression A Laboratory Manual, W.H. Freeman and Company, New York (1991) pp. 23-61.
Kriegler, DNA Transfer, Gene Transfer and Expression A Laboratory Manual, W.H. Freeman and Company, New York (1991) pp. 96-102.
Jin et al., "Human T Cell Response to the Surface Antigen of Hepatitis B Virus (HBsAg)," Journal of Experimental Medicine, 168:293-306, 1988.
Adorini et al., Exogenous Peptides Compete for the Presentation of Endogenous Antigens to Major Histocompatibility Complex Class II-restricted T Cells, Immunology Today 11:945-948, 1991.
Adorini and Nagy, Peptide Competition for Antigen Presentation, Immunology Today 11:21-24, 1990.
Adorini et al., Competition for Antigen Presentation in Living Cells Involves Exchange of Peptides Bound by Class II MHC Molecules, Nature 342:800-803, 1989.
Chicz et al., Predominant Naturally Processed Peptides Bound to HLA-DR1 are Derived from MHC-related Molecules and are heterogeneous in Size, Nature 358:764-768, 1992.
Rosen et al., "Dictionary of Immunology" published 1989 by Stockton Press (N.Y.), p. 23.
Sette et al., Random Association Between the Peptide Repertoire of A2.1 Class I and Several Different DR Class II Molecules, Journal of Immunology 147:3893-3900, 1991.
Urban et al., Biochemical Analysis of Naturally Processed Peptides Bound to Human Class II Molecules, J. Cell. Biochem., Keystone Symposia on Molecular & Cellular Biology, Supplement 160, 1992, p. 41:0262.
Adorini et al., Interaction of an Immunodominant Epitope with Ia Molecules in T-cell Activation, Proc. Natl. Acad. Sci. USA 85:5181-5185, 1988.
Adorini et al., In vivo Competition Between Self Peptides and Foreign Antigens in T-cell Activation, Nature 334:623-625, 1988.
Adorini et al., Mechanisms Influencing the Immunodominance of T Cell Determinants J. Experimental Medicine 168:2091-2104, 1988.
Babbitt et al., Antigenic Competition at the Level of Peptide-Ia Binding, Proc. Natl. Acad. Sci. USA 83:4509-4513, 1986.
Brodsky, The Invariant Dating Service, Nature 348:581-582, 1990.
Buus et al., Autologous Peptides Constitutively Occupy the Antigen Binding Site on Ia, Science 242:1045-1047, 1988.
Buus and Werdelin, Oligopeptide Antigens of the Angiotensin Lineage Compete for Presentation by Paraformaldehyde-treated Accessory Cells to T Cells, J. Immunology 136:459-465, 1986.
Collins et al., Processing of Exogenous Liposome-Encapsulated Antigens in vivo Generates Glass I MHC-Restricted T Cell Responses, J. Immunology 148:3336-3341, 1992.
De Magistris et al., Antigen Analog-Major Histocompatibility Complexes Act as Antagonists of the T Cell Receptor, Cell 68:625-634, 1992.
Demotz et al., Characterization of a Naturally Processed MHC Class II-restricted T-cell Determinant of Hen Egg Lysozyme, Nature 342:682-684, 1989.
Donermeyer and Allen, Binding to Ia Protects an Immunogenic Peptide from Proteolytic Degradation, J. Immunology 142:1063-1068, 1989.
Efraim and Liacopoulos, Inhibition of Delayed Hypersensitivity in Guinea-pigs after Competition Between Synthetic Antigens, Nature 711-713, 1967.
Falk et al., Cellular Peptide Composition Governed by Major Histocompatibility Complex Class I Molecules, Nature 348:248-251, 1990.
Falk et al., Allele-specific Motifs Revealed by Sequencing of Self-Peptides Eluted from MHC Molecules, Nature 351:290-296, 1991.
Falk et al., Identification of Naturally Processed Viral Nonapeptides Allows Their Quantification in Infected Cells and Suggests an Allele-specific T Cell Epitope Forecast, J. Exp. Med. 174:425-434, 1991.
Gorga, Structural Analysis of Class II Major Histocompatibility Complex Proteins Critical Reviews in Immunology 11:305-335, 1992.
Grey et al., Biologic Significance and Therapeutic Implications of Antigen/MHC Interactions, Clinical Immunology and Immunopathology 53:S47-S52, 1989.
Griem et al., Uneven Tissue Distribution of Minor Histocompatibility Proteins Versus Peptides is Caused by MHC Expression, Cell 65:633-640, 1991.
Guery et al., Selective Immunosuppression by Administration of Major Histocompatibility Complex (MHC) Class II-binding Peptides. I. Evidence for In Vivo . . . T Cell Activation, J. Exp. Med. 175:1345-1352, 1992.
Guillet et al., Interaction of Peptide Antigens and Class II Major Histocompatibility Complex Antigens, Nature 324:260-262, 1986.
Guttinger et al., Human T Cells Recognize Polymorphic and Non-Polymorphic Regions of the Plasmodium falciparum Circumsporozoite Protein, EMBO Journal 7:2555-2558, 1988.
Harding et al., Liposome-Encapsulated Antigens are Processed in Lysosomes, Recycled, and Presented to T Cells, Cell 64:393-401, 1991.
Harris et al., MHC Class II Binding of Peptides Derived from HLA-DR 1, J. Immunology 148:2169-2174, 1992.
Henderson et al., HLA-A2.1--Associated Peptides from a Mutant Cell Line: A Second Pathway of Antigen Presentation, Science 255:1264-1266, 1992.
Hill et al., Conformational and Structural Characteristics of Peptides Binding to HLA-DR Molecules, J. Immunology 147:189-197, 1991.
Hunt et al., Characterization of Peptides Bound to the Class II MHC Molecule HLA-A2.1 by Mass Spectrometry, Science 255:1261-1263, 1992.
Hunt et al., Peptides Presented to the Immune System by the Murine Class II Major Histocompatibility Complex Molecule I-A, Science 256:1817-1820, 1992.
Janeway, Immunotherapy by Peptides?, Nature 341:482-483, 1989.
Jardetzky et al., Identification of Self Peptides Bound to Purified HLA-B27, Nature 353:326-328, 1991.
Jones et al., Detection of a Common Polypeptide Chain in I-A and I-E Sub-region Immunoprecipitates, Immunochemistry 16:51-60, 1978.
Kilgus et al., Vaccine T-cell Epitope Selection by a Peptide Competition Assay, Proc. Natl. Acad. Sci. USA 86:1629-1633, 1989.
Kropshofer et al., Pool Sequencing of Self Peptides Released from HLA-DR Rationalizes Allele Unspecific Binding Via Apolar Side-chains, PS-M-5 (MS-02-5) p. 249.
Kropshofer et al., Self-Peptide Release from Class II HLA-DR1 Exhibits a Hydrophobic Two-Residue Contact Motif, J. Exp. Med. 175:1799-1803, 1992.
Lakey et al., Peptides Related to the Antigenic Determinant Block T Cell Recognition of the Native Protein as Process by Antigen-presenting Cells, Eur. J. Immunol. 16:721-727, 1986.
Lamont et al., The Use of Peptide Analogs with Improved Stability and MHC Binding Capacity to Inhibit Antigen Presentation in vitro and in vivo, J. Immunology 144:2493-2498, 1990.
Lamont et al., Inhibition of Experimental Autoimmune Encephalomyelitis Induction in SJL/J Mice by Using a Peptide with High Affinity for IA Molecules, J. Immunology 145:1687-1693, 1990.
Lanzavecchia et al., Irreversible Association of Peptides with Class II MHC Molecules in Living Cells, Nature 357:249-252, 1992.
Lehmann et al., Inhibition of T Cell Response with Peptides is Influenced by Both Peptide-binding Specificity of . . . Molecules and Susceptibility of T Cells to Blocking, Eur. J. Immunol. 19:1071-1077, 1989.
Margulies et al., Engineering Soluble Major Histocompatibility Molecules: Why and How, Immunol. Res. 6:101-116, 1987.
Maryanski et al., Competitor Analogs for Defi
Chicz Roman M.
Hedley Mary Lynne
Stern Lawrence J.
Strominger Jack L.
Urban Robert Glen
President and Fellows of Harvard College
Stanton Brian R.
LandOfFree
Immunomodulatory peptides does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Immunomodulatory peptides, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Immunomodulatory peptides will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1321220